Declining Profitability and Impairment Losses in the Life Sciences and Equipment Development Business
First written in FY2018-Q3. 14 of 30 entries say "Worsened", first in FY2018. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026MitigatedAnnual report
「The Life Sciences and Equipment Development business reported revenue of ¥284.392 million, up 28.9% year on year, and a segment loss of ¥36.679 million, compared with a segment loss of ¥52.055 million in the previous fiscal year.」
Revenue increased, and the segment loss narrowed from ¥52.055 million to ¥36.679 million. However, it continued to report a loss. - FY2026-H1MitigatedAnnual report
「As a result, revenue was ¥51.974 million, up 66.3% year on year, and the segment loss was ¥62.574 million, compared with a loss of ¥76.951 million in the same period of the previous year.」
The Life Sciences and Equipment Development business recorded higher revenue, while the segment loss narrowed from ¥76.951 million in the same period of the previous year to ¥62.574 million. However, it continued to report a loss. - FY2025-H1WorsenedAnnual report
「As a result, revenue was ¥31.255 million, down 17.4% year on year, and the segment loss was ¥76.951 million, compared with a loss of ¥60.672 million in the same period of the previous year.」
The Life Sciences and Equipment Development business recorded lower revenue, while the segment loss widened from ¥60.672 million in the same period of the previous year to ¥76.951 million. - FY2024WorsenedAnnual report
「The Life Sciences and Equipment Development business reported revenue of ¥330.303 million, up 1.7% year on year, and a segment loss of ¥25.659 million, compared with segment profit of ¥1.533 million in the previous fiscal year.」
The business turned from segment profit in the previous fiscal year to a loss of ¥25.659 million. It also recorded an impairment loss of ¥23.857 million on research and development equipment. - FY2024-Q3MitigatedAnnual report
「As a result, revenue was ¥66.862 million, up 18.5% year on year, and the segment loss was ¥85.972 million, compared with a loss of ¥88.109 million in the same quarter of the previous year.」
The Life Sciences and Equipment Development business recorded higher revenue, while the segment loss narrowed from ¥88.109 million in the same period of the previous year to ¥85.972 million. However, it continued to report a loss and also recorded an impairment loss of ¥1.837 million. - FY2024-Q2MitigatedAnnual report
「As a result, revenue was ¥37.453 million, up 100.3% year on year, and the segment loss was ¥60.672 million, compared with a loss of ¥66.563 million in the same period of the previous year.」
The Life Science and Equipment Development Business increased revenue, and its segment loss narrowed from ¥66.563 million in the same period of the previous year to ¥60.672 million. However, it continued to report a loss. - FY2024-Q1MitigatedAnnual report
「As a result, revenue was ¥6.933 million, down 14.1% year on year, and the segment loss was ¥37.150 million, compared with a loss of ¥39.134 million in the same period of the previous year. The Company recorded an impairment loss of ¥442 thousand in the Life Science and Equipment Development Business segment due to declining profitability.」
Although the business continued to report lower revenue and a loss, the segment loss narrowed from ¥39.134 million in the same period of the previous year to ¥37.150 million, and the impairment loss declined from ¥2.400 million to ¥442 thousand. - FY2023-Q3WorsenedAnnual report
「As a result, revenue was ¥56.446 million, down 62.5% year on year, and the segment loss was ¥88.109 million, compared with a loss of ¥40.095 million in the same period of the previous year.」
The Life Science and Equipment Development Business reported a substantial decline in revenue, and its segment loss expanded from ¥40.095 million in the same period of the previous year to ¥88.109 million. It also recorded an impairment loss of ¥2.803 million due to declining profitability. - FY2023-Q2WorsenedAnnual report
「As a result, revenue was ¥18.697 million, down 84.0% year on year, and the segment loss was ¥66.563 million, compared with a loss of ¥21.585 million in the same period of the previous year.」
The Life Science and Equipment Development Business reported a substantial decline in revenue, and its segment loss expanded from ¥21.585 million in the same period of the previous year to ¥66.563 million. - FY2023-Q1WorsenedAnnual report
「As a result, revenue was ¥8.070 million, down 49.6% year on year, and the segment loss was ¥39.134 million, compared with a loss of ¥34.464 million in the same period of the previous year.」
Revenue in the Life Science and Equipment Development Business declined, and the segment loss expanded from ¥34.464 million in the same period of the previous year to ¥39.134 million. The business also recorded an impairment loss of ¥2.400 million due to declining profitability. - FY2022MitigatedAnnual report
「The Life Science and Equipment Development Business reported revenue of ¥262.552 million and a segment profit of ¥5.795 million.」
The business, which had reported a segment loss of ¥40.095 million for the nine-month period, reported a segment profit of ¥5.795 million for the full fiscal year. Meanwhile, an impairment loss of ¥578 thousand on research and development equipment was recorded. - FY2022-Q3WorsenedAnnual report
「As a result, revenue was ¥150.689 million and the segment loss was ¥40.095 million. The Company recorded an impairment loss of ¥578 thousand in the Life Science and Equipment Development Business segment due to declining profitability.」
The segment loss in the Life Science and Equipment Development Business expanded from ¥21.585 million for the six-month period to ¥40.095 million for the nine-month period, and an impairment loss of ¥578 thousand due to declining profitability was also recorded. - FY2022-Q2MitigatedAnnual report
「As a result, revenue was ¥117.192 million and the segment loss was ¥21.585 million.」
The Life Science and Equipment Development Business continued to report a loss, but revenue increased and the loss narrowed from revenue of ¥16.017 million and a segment loss of ¥34.464 million in the first quarter. - FY2022-Q1First quarter: revenue recognized and loss reportedAnnual report
「Revenue was not expected to be significant from the outset in the first quarter, and the Company recorded revenue from MakCell and consumables-related products, among other sources. [Excerpt] As a result, revenue was ¥16.017 million and the segment loss was ¥34.464 million.」
While revenue from MakCell and consumables-related products was recorded, the Life Science and Equipment Development Business reported revenue of ¥16.017 million and a segment loss of ¥34.464 million. - FY2021-Q3WorsenedAnnual report
「As a result, revenue was ¥47.848 million, down 66.1% year on year, and the segment loss was ¥101.523 million, compared with a loss of ¥54.544 million in the same period of the previous year.」
The Life Science and Equipment Development Business reported lower revenue, and its segment loss expanded from ¥54.544 million in the same period of the previous year to ¥101.523 million. - FY2021-Q2The six-month cumulative period saw lower revenue and a wider lossAnnual report
「As a result, revenue was ¥23.772 million, down 77.6% year on year, and the segment loss was ¥54.604 million, compared with a loss of ¥40.629 million in the same period of the previous year.」
The Life Science and Equipment Development Business reported lower revenue, and its segment loss expanded from ¥40.629 million in the same period of the previous year to ¥54.604 million. - FY2021-Q1WorsenedAnnual report
「As a result, revenue was ¥4.967 million, down 71.7% year on year, and the segment loss was ¥39.512 million, compared with a loss of ¥27.974 million in the same period of the previous year.」
The Life Science and Equipment Development Business reported lower revenue, and its segment loss expanded from ¥27.974 million in the same period of the previous year to ¥39.512 million. - FY2020MitigatedAnnual report
「The Life Science and Equipment Development Business reported revenue of ¥194.392 million, up 96.3% year on year, and a segment loss of ¥24.509 million, compared with a segment loss of ¥58.977 million in the previous fiscal year.」
Although the business continued to report a segment loss, revenue increased and the loss narrowed from ¥58.977 million to ¥24.509 million. - FY2020-Q3MitigatedAnnual report
「As a result, revenue was ¥141.154 million, up 82.7% year on year, and the segment loss was ¥54.544 million, compared with a loss of ¥73.323 million in the same period of the previous year.」
The Life Science and Equipment Development Business increased revenue, and its segment loss narrowed from ¥73.323 million in the same period of the previous year to ¥54.544 million. However, it continued to report a segment loss. - FY2020-Q2WorsenedAnnual report
「As a result, revenue was ¥105.918 million, up 60.9% year on year, and the segment loss was ¥40.629 million, compared with a loss of ¥35.596 million in the same period of the previous year.」
Although revenue increased, the segment loss expanded from ¥35.596 million in the same period of the previous year to ¥40.629 million, and the decline in profitability has continued. - FY2020-Q1MitigatedAnnual report
「As a result, revenue was ¥17.541 million, up 278.3% year on year, and the segment loss was ¥27.974 million, compared with a loss of ¥33.353 million in the same period of the previous year.」
The Life Science and Equipment Development Business increased revenue year on year, and its segment loss narrowed from ¥33.353 million to ¥27.974 million. However, it continued to report a segment loss. - FY2019MitigatedAnnual report
「The Life Science and Equipment Development Business reported revenue of ¥99.025 million, down 6.8% year on year, and a segment loss of ¥58.977 million, compared with a segment loss of ¥75.538 million in the previous fiscal year.」
The business remained loss-making and also recorded an impairment loss of ¥1.037 million on research and development equipment, but the segment loss narrowed from the previous fiscal year, as did the impairment loss from ¥26.556 million in the previous fiscal year. - FY2019-Q3WorsenedAnnual report
「As a result, revenue was ¥77.266 million, down 6.3% year on year, and the segment loss was ¥73.323 million, compared with a loss of ¥52.926 million in the same period of the previous year.」
The segment loss in the Life Science and Equipment Development Business expanded from ¥52.926 million in the same period of the previous year to ¥73.323 million. An impairment loss of ¥185 thousand due to declining profitability was also recorded. - FY2019-Q2WorsenedAnnual report
「As a result, revenue was ¥65.812 million, down 2.6% year on year, and the segment loss was ¥35.596 million, compared with a loss of ¥11.052 million in the same period of the previous year. [Excerpt] During the six-month period, the Company recorded an impairment loss of ¥185 thousand in the Life Science and Equipment Development Business segment due to declining profitability.」
The segment loss in the Life Science and Equipment Development Business expanded from ¥11.052 million in the same period of the previous year to ¥35.596 million, and an impairment loss of ¥185 thousand due to declining profitability was also recorded. - FY2019-Q1WorsenedAnnual report
「In the first quarter, the Life Science and Equipment Development Business conducted manufacturing activities in preparation for delivery. As a result, revenue was ¥4.637 million, down 91.3% year on year, and the segment reported a loss of ¥33.353 million, compared with a profit of ¥2.555 million in the same period of the previous year.」
The business swung from a segment profit of ¥2.555 million in the same period of the previous year to a segment loss of ¥33.353 million, and the decline in profitability has continued. - FY2018WorsenedAnnual report
「The Life Science and Equipment Development Business reported revenue of ¥106.227 million, up 10.3% year on year, and a segment loss of ¥100.575 million, compared with a segment loss of ¥60.380 million in the previous fiscal year.」
The segment loss in the business expanded from ¥60.380 million in the previous fiscal year to ¥100.575 million. The Company also recorded an impairment loss of ¥26.556 million on R&D equipment and other assets, and the decline in profitability has continued. - FY2018-Q3First statedAnnual report
「The Company recorded an impairment loss of ¥18.261 million in the Life Science and Equipment Development Business segment due to declining profitability.」
The decline in profitability materialized, and an impairment loss of ¥18.261 million was recorded.